Evaluation of blood glucose control in ICU patients with Space GlucoseControl: a European study
- 288 Downloads
KeywordsGlycaemia Control Model Predictive Control Target Range Clinical Decision Support Clinical Decision Support System
Regardless of the ongoing debate on optimum target ranges, glycaemia control (GC) remains an important therapeutic goal in critically ill patients. Dozens of different insulin protocols for ICUs have been developed with different complexity, effectiveness, blood glucose (BG) variability and safety. Although comparison of existing protocols is difficult due to significant differences in processes and outcome measures, computerized clinical decision support systems generally achieved better GC with consistently lower hypoglycaemia rates than that achieved with paper-based protocols . The enhanced Model Predictive Control (eMPC) algorithm, developed by the CLINICIP group, is the effective clinically proven protocol, which has been successfully tested at multiple institutions on medical and surgical patients with different nutritional protocols [2, 3]. The eMPC models the behaviour of glucose and insulin in ICU patients with a variable sample interval based on the accuracy of the BG prediction. It has been integrated in the B.Braun Space GlucoseControl (SGC) system, which allows direct data communication between pumps and Space Control with the incorporated eMPC algorithm. Although SGC is already clinically used in dozens of ICUs worldwide, there are few only published experiences with its use .
The primary objective of this multicentre European noninterventional study was to evaluate the performance (efficiency) of SGC under routine conditions in adult ICU patients requiring BG control. The primary endpoint was the percentage of time within the target range, and secondary outcome measures were the frequency of hypoglycaemic episodes and BG measurement intervals. Patients in this trial were assigned to the target range 4.4 to 8.3 mmol/l. Nutritional management (enteral, parenteral or both) was carried out at the discretion of the each centre.
Seventeen centres from nine European countries included a total of 508 patients. During the study a total of 29,575 BG values were entered into the SGCs and the same number of recommendations were rendered. The mean time-in-target was 77.5 ± 20.9%. The mean proposed next measurement time was 2.0 ± 0.5 hours. Only four episodes of hypoglycaemia <2.2 mmol/l occurred (0.01% of measurements).
SGC is a safe and very efficient system to control BG in ICU patients.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.